Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$22.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 48.33% year-over-year to -$22.4 million in Q2 2026; TTM through Jun 2026 was -$92.5 million, a 56.09% increase from a year earlier, with the FY2025 full-year figure at -$147.5 million, up 29.86% from the prior year.
• Net Income towards Common Stockholders was -$22.4 million for Q2 2026 at Pliant Therapeutics, down from -$22.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$21.7 million in Q4 2025 and troughed at -$61.6 million in Q2 2024.
• A 5-year average of -$39.1 million and a median of -$39.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 49.63% in 2024 and surged 63.11% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$35.1 million in 2022, then declined by 17.25% to -$41.1 million in 2023, then retreated by 20.98% to -$49.7 million in 2024, then soared by 56.27% to -$21.7 million in 2025, then fell by 2.86% to -$22.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$22.4 million (Q2 2026), -$22.1 million (Q1 2026), and -$21.7 million (Q4 2025), per Business Quant data.